Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 30, Number 11—November 2024
Research Letter

Mpox Hepatic and Pulmonary Lesions in HIV/Hepatitis B Virus Co-Infected Patient, France

Ruxandra CalinComments to Author , Claire Périllaud-Dubois, Stéphane Marot, Khaldoun Kerrou, Gilles Peytavin, Marwa Bachir, Anne Laure Kirch, Ludovic Lassel, Vincent Fallet, Joel Gozlan, Jean Baptiste Pain, Patricia Senet, Olivier Ferraris, Sébastien Bine, Mathieu Hubert, Olivier Schwartz, Laurence Morand-Joubert, and Gilles Pialoux
Author affiliation: Author affiliations: Sorbonne University Tenon Hospital, Paris, France (R. Calin, K. Kerrou, M. Bachir, A.L. Kirch, L. Lassel, V. Fallet, J.B. Pain, P. Senet, G. Pialoux); Sorbonne University Saint-Antoine Hospital, Paris (C. Périllaud-Dubois, J. Gozlan, L. Morand-Joubert); Sorbonne University Pitié-Salpêtrière Hospital, Paris (S. Marot); Université Paris Cité Bichat Claude Bernard Hospital, Paris (G. Peytavin); Institut de Recherche Biomédicale des Armées National Reference Center for Orthopoxviruses, Brétigny-sur-Orge, France (O. Ferraris); Directorate-General for Health, Paris (S. Bine); Université Paris Cité Institut Pasteur, Paris (M. Hubert, O. Schwartz)

Main Article

Table

MPXV antibody titers in case study of mpox hepatic and pulmonary lesions in HIV/hepatitis B virus co-infected patient, France*

Date No. days after mpox diagnosis MPXV E8L IgG titer,† AU/mL MPXV NAb titer without complement‡ MPXV NAb titer with complement‡
2022 Sep 21 35 186 160 1,280
2022 Oct 17 61 >400 0 1,280
2022 Nov 16 91 >400 40 2,560
2023 Jan 6 142 >400 1,280 2,560
2023 Jan 10 146 >400 640 2,560
2023 Feb 14 181 >400 320 2,560

*AU, arbitrary unit; MPXV, monkeypox virus; NAb, neutralizing antibody. †IgG against MPXV E8L protein was measured by using the Monkeypox Virus E8L Protein Human IgG ELISA Kit (RayBiotech, https://www.raybiotech.com). All serum samples were positive and reached the upper limit of detection (400 AU/mL) by 2 months after mpox diagnosis. ‡MPXV neutralizing antibody titers were determined in serum samples with or without added complement, as previously described (5). Nab titers decreased in serum samples without added complement when new skins lesions appeared and older lesions deteriorated; NAbs only increased after the first injection of vaccinia immune globulins. However, Nab titers were higher when complement was added to the assay and did not decrease; we did not see an increase after the first or second vaccinia immune globulins injections. Upper limit of MPXV neutralization titer was 1:2,560.

Main Article

References
  1. World Health Organization. Multi-country outbreak of mpox: external situation report 31. December 22, 2023 [cited 2024 May 23]. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20231222_mpox_external-sitrep_31.pdf
  2. Mitjà  O, Alemany  A, Marks  M, Lezama Mora  JI, Rodríguez-Aldama  JC, Torres Silva  MS, et al.; SHARE-NET writing group. Mpox in people with advanced HIV infection: a global case series. Lancet. 2023;401:939–49. DOIPubMedGoogle Scholar
  3. Shishido  AA, Street  S. Optimal management of severe mpox in patients with uncontrolled human immunodeficiency virus. J Med Virol. 2023;95:e29277. DOIPubMedGoogle Scholar
  4. Harris  E. As mpox cases surge in Africa, WHO declares a global emergency—here’s what to know. JAMA. 2024;332:862–4. DOIPubMedGoogle Scholar
  5. Hubert  M, Guivel-Benhassine  F, Bruel  T, Porrot  F, Planas  D, Vanhomwegen  J, et al. Complement-dependent mpox-virus-neutralizing antibodies in infected and vaccinated individuals. Cell Host Microbe. 2023;31:937–948.e4. DOIPubMedGoogle Scholar
  6. Triana-González  S, Román-López  C, Mauss  S, Cano-Díaz  AL, Mata-Marín  JA, Pérez-Barragán  E, et al. Risk factors for mortality and clinical presentation of monkeypox. AIDS. 2023;37:1979–85. DOIPubMedGoogle Scholar
  7. Martinez  AE, Frattaroli  P, Vu  CA, Paniagua  L, Mintz  J, Bravo-Gonzalez  A, et al. Successful outcome after treatment with cidofovir, vaccinia, and extended course of tecovirimat in a newly-diagnosed HIV patient with severe mpox: a case report. Vaccines (Basel). 2023;11:650. DOIPubMedGoogle Scholar
  8. Miller  MJ, Cash-Goldwasser  S, Marx  GE, Schrodt  CA, Kimball  A, Padgett  K, et al.; CDC Severe Monkeypox Investigations Team. Severe monkeypox in hospitalized patients—United States, August 10–October 10, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:1412–7. DOIPubMedGoogle Scholar
  9. Simadibrata  DM, Lesmana  E, Pratama  MIA, Annisa  NG, Thenedi  K, Simadibrata  M. Gastrointestinal Symptoms of Monkeypox Infection: A systematic review and meta-analysis. J Med Virol. 2023;95:e28709. DOIPubMedGoogle Scholar
  10. Grosenbach  DW, Honeychurch  K, Rose  EA, Chinsangaram  J, Frimm  A, Maiti  B, et al. Oral tecovirimat for the treatment of smallpox. N Engl J Med. 2018;379:44–53. DOIPubMedGoogle Scholar

Main Article

Page created: September 13, 2024
Page updated: October 23, 2024
Page reviewed: October 23, 2024
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external